Oncotarget · 2015 · 84 citations · 48 references
MedicineOncologyPharmacologyApoptosisMolecular OncologyOncogenesCytotoxic ChemotherapyEnzyme InhibitionMyc Family OncogenesPharmacodynamics Of Anticancer AgentsApoptosis TargetingJnk Signaling PathwayMapk SignalingMek InhibitionMek InhibitorsMyc InhibitorsMyc OverexpressionTherapeutic Targeting Of Myc
// Qiaoli Zhao 1 , Andreana N. Assimopoulou 2 , Sabine M. Klauck 3 , Harilaos Damianakos 4 , Ioanna Chinou 4 , Nadine Kretschmer 5 , José-Luis Rios 6 , Vassilios P. Papageorgiou 2 , Rudolf Bauer 5 , Thomas Efferth 1 1 Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Mainz, Germany 2 Department of Chemical Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece 3 Working Group Cancer Genome Research, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), National Center for Tumor Diseases (NCT), Heidelberg, Germany 4 Faculty of Pharmacy, University of Athens, Athens, Greece 5 Department of Pharmacognosy, Institute of Pharmaceutical Sciences, University of Graz, Graz, Austria 6 Department de Farmacologia, Facultat de Farmàcia, Universitat de València, Valencia, Spain Correspondence to: Thomas Efferth, e-mail: efferth@uni-mainz.de Keywords: shikonin and its derivatives, c-MYC, ERK/JNK/MAP kinases, AKT pathway, acute leukemia Received: July 09, 2015 Accepted: September 28, 2015 Published: October 09, 2015 ABSTRACT Leukemia remains life-threatening despite remarkable advances in chemotherapy. The poor prognosis and drug resistance are challenging treatment. Novel drugs are urgently needed. Shikonin, a natural naphthoquinone, has been previously shown by us to be particularly effective towards various leukemia cell lines compared to solid tumors. However, the underlying mechanisms are still poorly understood. Here, we investigated shikonin and 14 derivatives on U937 leukemia cells. Four derivatives (isobutyrylshikonin, 2-methylbutyrylshikonin, isovalerylshikonin and β,β-dimethylacrylshikonin) were more active than shikonin. AnnexinV-PI analysis revealed that shikonins induced apoptosis. Cell cycle G1/S check point regulation and the transcription factor c-MYC, which plays a vital role in cell cycle regulation and proliferation, were identified as the most commonly down-regulated mechanisms upon treatment with shikonins in mRNA microarray hybridizations. Western blotting and DNA-binding assays confirmed the inhibition of c-MYC expression and transcriptional activity by shikonins. Reduction of c-MYC expression was closely associated with deregulated ERK, JNK MAPK and AKT activity, indicating their involvement in shikonin-triggered c-MYC inactivation. Molecular docking studies revealed that shikonin and its derivatives bind to the same DNA-binding domain of c-MYC as the known c-MYC inhibitors 10058-F4 and 10074-G5. This finding indicates that shikonins bind to c-MYC. The effect of shikonin on U937 cells was confirmed in other leukemia cell lines (Jurkat, Molt4, CCRF-CEM, and multidrug-resistant CEM/ADR5000), where shikonin also inhibited c-MYC expression and influenced phosphorylation of AKT, ERK1/2, and SAPK/JNK. In summary, inhibition of c-MYC and related pathways represents a novel mechanism of shikonin and its derivatives to explain their anti-leukemic activity.
48
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
Rosalie C. Sears, Faison Nuckolls, Eric B. Haura et al. · Genes & Development · 2000 · 1.4K citations · Full text
Analysis of gene expression in single live neurons.
Jim Eberwine, Helena Yeh, Kevin Miyashiro et al. · Proceedings of the National Academy of Sciences · 1992 · 959 citations
A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1
Reino Heikkilä, G Schwab, Eric Wickstrom et al. · Nature · 1987 · 691 citations